Table 2.
Donor characteristics
| Donor characteristics | Non-improver (NI) | Mild-improver (MI) | Improver (I) | Significant? |
|---|---|---|---|---|
| Age | 70 (65–82) | 73 (68–81) | 69 (65–69) | ns |
| Gender | 3 Male; 4 Female | 2 Male; 2 Female | 1 Male; 6 Female | |
| VZV clinical score at baseline | 1 | 0.5 | 3 | ***NI vs. I |
| CRP at baseline (mg/l) | 0.8 (0.3–24.3) | 0.7 (0.3–24.3) | 0.8 (0.4–2.6) | ns |
| Serum 25(OH)D at baseline (nmol/l) | 40.0 (23–68) | 53.0 (37–65) | 42.0 (22–71)) | ns |
| Serum 25(OH)D after Vitamin D3 supplementation (nmol/l) | 89.0 (47–102) | 103.5 (87–118) | 78.0 (50.0–136.0) | ns |
| Change in clinical score | 0 | 1 | 2 | *** NI vs. I |
| Number of donors | 7 | 4 | 7 |
Non-improvers VZV clinical score change of 0, mild improvers VZV clinical score change of 1 and improvers VZV clinical score change of >1 after vitamin D3 supplementation. Data shown as median ± 10-90 Percentile. Data analysed by Kruskal–Wallis test.
ns, non-significant; VZV, varicella zoster virus.
***P < 0.001.